6. Coconut oil
The MCT-like saturated fat — lauric acid, antimicrobial activity, and a contested health profile.
Coconut oil in 1 minute
What does it provide? A high-smoke-point (≈ 175–204 °C) tropical cooking fat with ≈ 82–92% saturated fatty acids — dominantly lauric acid (C12, ≈ 47% — converts to antimicrobial monolaurin in the stomach, in vitro active against Gram-positives and Candida). NOT a classic MCT oil: C12 behaves like a long-chain fatty acid (incorporated into chylomicrons, does NOT travel via portal vein to the liver). Khaw 2018 RCT[1919] and AHA 2017 advisory[1917]: consistently raises LDL cholesterol by 10–15 mg/dL vs. olive oil.
How much? Maximum 1–2 tablespoons (15–30 g) per day, mainly in tropical cuisine (Thai/Indian/Indonesian curry) — NOT an everyday cooking fat in a Western diet. "Bulletproof coffee" as a daily routine is not recommended.
When to avoid? Confirmed high LDL cholesterol or familial hypercholesterolemia (ApoE ε4/ε4 genotype is particularly sensitive); confirmed ASCVD (AHA 2017 opposes); NAFLD/NASH (SFA reduction is part of treatment); acute pancreatitis or acute gallstone attack (fat restriction); cystic fibrosis without enzyme replacement; coconut IgE allergy (rare but exists); severe insulin resistance with metabolic syndrome.
Coconut (Cocos nucifera) has been a foundational food of Pacific and Indian Ocean coastal cultures for millennia — revered in Polynesian water culture as the "king of trees" ("te ariki o te rakau"), covering every life stage in roles as hydration (coconut water), food (coconut meat), building material (fiber, shell), and lighting fuel (oil). The Malay word "kelapa" became the Portuguese "coco" — Vasco da Gama's sailors named it after the spiky-hairy coconut's face-like shape ("coco" in Portuguese = grinning ghost head).
From the mid-20th century, coconut oil featured in the "tropical oil" category as a base material for margarine production. The 1960–80s dietary guidelines (Ancel Keys paradigm) classified it as definitely-to-be-avoided due to high SFA content. In the 2000–2010s, "bulletproof coffee," the ketogenic movement, and Dave Asprey-style wellness positioning celebrated coconut oil as a miracle — labeled "superfood," "smart fat," "MCT bomb." In 2017, the American Heart Association scientific advisory (Sacks et al., Circulation 2017) firmly opposed coconut oil: human RCTs consistently showed LDL-raising effect, and there is no evidence to offset this with clinical outcome benefits. The realistic picture: coconut oil is a good flavor carrier for tropical cuisine, usable for medium-heat cooking, but the "superfood" character is significantly marketing-driven.
Scientific Background
Coconut oil's fatty acid profile is unique: about 82–92% saturated fatty acids, with the dominant being lauric acid (C12, about 47%).[1890] Lauric acid was traditionally classified among "medium-chain triglycerides" (MCTs) because of its carbon count (C12) — however, by modern lipid chemistry classification, lauric acid metabolically behaves more like a long-chain fatty acid: incorporated into chylomicrons in the small intestine, not transported via the portal vein (as classic C6–C10 MCTs are).[1923] So the "coconut oil = MCT" argument is partly false.
Human RCT evidence (Eyres 2016 review[1918], Khaw 2018 RCT): coconut oil consumption consistently raises LDL cholesterol vs. plant oil substitution (about +10–15 mg/dL)[1920], and also raises HDL moderately — the net effect on CVD risk is likely negative. The AHA 2017 advisory (Sacks et al., Circulation 2017) therefore clearly opposes coconut oil as an everyday dietary fat. Population evidence (tropical populations with traditional coconut-rich diet) cannot be extrapolated to Western dietary context — the overall dietary matrix, physical activity, and genetic background differ fundamentally.
At the microbiome level there are in vitro antimicrobial data: lauric acid and monolaurin (the monoglyceride derivative of lauric acid) inhibit certain Gram-positive bacteria, Candida species, and even enveloped viruses.[1922] Human gut-flora evidence is limited — small-intestinal microbiota modulation is expected, but robust clinical RCTs are absent. Statements like "coconut oil kills Candida" are extrapolation of in vitro data to clinical indication — not rigorous.
Virgin (cold-pressed) coconut oil contains small amounts of polyphenols (caffeic acid derivatives)[1921]; the refined (RBD — refined, bleached, deodorized) version loses these. The absolute amount of polyphenols, however, is low — not comparable to olive or walnut oil.
- + Tropical spices (turmeric, ginger, cumin, garlic): classic Southeast Asian cuisine — coconut oil is the flavor carrier of the spices.
- + Legumes (lentils, red lentils, beans) in tropical curry style: the coconut milk + coconut oil curry base is the foundation of Thai, Indonesian, and South Indian cuisine, fiber-fat-spice synergy.
- + High-temperature stir-frying of vegetables, fish (short duration): medium-high smoke point (175–204 °C) usable for frying.
- + Sweet pattern: coconut oil + cocoa + dates: "raw" chocolate base.
- + With coconut milk + coconut meat: coherent tropical matrix, fiber + fat + water together.
- + With high-vitamin-C fruits (mango, pineapple, papaya): protection against lipid peroxidation.
- + External use (skin, hair — not a dietary indication): moisturizing, lipid replacement — skin microbiota research is active.
- Fat replacement with high LDL levels: the "coconut oil is healthy, I can eat it" mindset can worsen dyslipidemia. The LDL-raising effect is documented.
- Statin therapy + high-dose coconut oil consumption: theoretical SFA-driven LDL elevation can reduce statin efficacy. Moderation.
- Coconut "bulletproof coffee" as a daily routine on an unbalanced diet: calorie excess + SFA excess + flavor-based "appetite conditioning" — not a weight-loss strategy but a CVD-risk-raising pattern for many.
- Hydrogenated "palm-kernel" coconut substitute oils ("coconut shortening"): cheap commercial products may be partially hydrogenated — trans-fat content, seriously harmful. Read labels.
- Severe steatorrhea, exocrine pancreatic insufficiency: fat restriction is mandatory.
- Coconut allergy (rare but exists): strict avoidance. Coconut does NOT belong to tree-nut allergens (botanically it's a drupe seed, not a nut) — cross-reactivity with other tree nuts is rare.
- Familial hypercholesterolemia, confirmed ASCVD: the AHA 2017 advisory specifically opposes coconut oil in this population.
- NAFLD/NASH: SFA reduction is part of treatment — coconut oil is not a priority.
- Acute pancreatitis, acute cholesterol gallstone attack: fat restriction is mandatory.
- ApoE ε4/ε4 genotype: higher SFA sensitivity — individual LDL monitoring is mandatory.
- Coconut IgE-mediated allergy (rare): strict avoidance.
- Severe insulin resistance with metabolic syndrome: routine coconut oil intake is not supported by evidence.
- Pregnancy and breastfeeding: small-moderate amounts are safe; "superfood"-style daily large doses are not justified.
- Cystic fibrosis, exocrine pancreatic insufficiency: without enzyme replacement (pancreatin), fat absorption is impaired.
Daily serving: maximum 1–2 tablespoons (15–30 g) — mainly for tropical cuisine, in moderation.
Preparation methods:
- Thai/Indian/Indonesian curry base: coconut oil + spice paste (yellow, red, green curry) → tropical cuisine foundation.
- Wok cooking: short-duration, high-temperature stir-frying of vegetables, fish, shrimp.
- Toasting: granola toasted with coconut flakes and coconut oil.
- In sweets: raw chocolate bonbon base (coconut oil + cocoa + sweetener).
- Coconut rice: jasmine/basmati rice + coconut milk + drops of coconut oil.
Classic patterns:
- Thai red curry: coconut oil + red curry paste + coconut milk + vegetables + tofu/chicken + Thai basil + fish sauce
- South Indian sambar: red lentil + vegetables + coconut-oil "tarka" (pungent spices) + grated coconut
- Indonesian nasi goreng: rice + coconut oil + sambal + egg + vegetables
- Polynesian fish: fish fillet + coconut milk sauce + lime + chili + cilantro
Storage: at room temperature, in a dark place, in an airtight jar — solid below 25 °C, liquid above. Keeps 12–18 months. Rock-hard in the refrigerator; can be liquefied by warming.
What not to do: Do NOT use as a daily cooking fat in a Western diet with high LDL, do NOT believe the "superfood" marketing, do NOT mix hydrogenated "palm-kernel" substitute with real coconut oil.
References
[1890] EFSA Panel. Scientific Opinion on Dietary Reference Values for fats. EFSA Journal 2010;8(3):1461. . 2010. Link
EFSA Panel scientific opinion on Dietary Reference Values for fats.
[1917] Sacks FM et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation 2017;136(3):e1–e23. . 2017. Link
Cardiovascular disease (CVD) is the leading global cause of death, accounting for 17.3 million deaths per year. Preventive treatment that reduces CVD by even a small percentage can substantially reduce, nationally and globally, the number of people who develop CVD and the costs of caring for them. This American Heart Association presidential advisory on dietary fats and CVD reviews and discusses the scientific evidence, including the most recent studies, on the effects of dietary saturated fat intake and its replacement by other types of fats and carbohydrates on CVD. In summary, randomized controlled trials that lowered intake of dietary saturated fat and replaced it with polyunsaturated vegetable oil reduced CVD by ≈30\%, similar to the reduction achieved by statin treatment. Prospective observational studies in many populations showed that lower intake of saturated fat coupled with higher intake of polyunsaturated and monounsaturated fat is associated with lower rates of CVD and of other major causes of death and all-cause mortality. In contrast, replacement of saturated fat with mostly refined carbohydrates and sugars is not associated with lower rates of CVD and did not reduce CVD in clinical trials.
[1918] Eyres L et al. Coconut oil consumption and cardiovascular risk factors in humans. Nutr Rev 2016;74(4):267–280. . 2016. Link
Coconut oil is being heavily promoted as a healthy oil, with benefits that include support of heart health. To assess the merits of this claim, the literature on the effect of coconut consumption on cardiovascular risk factors and outcomes in humans was reviewed. Twenty-one research papers were identified for inclusion in the review: 8 clinical trials and 13 observational studies. The majority examined the effect of coconut oil or coconut products on serum lipid profiles. Coconut oil generally raised total and low-density lipoprotein cholesterol to a greater extent than cis unsaturated plant oils, but to a lesser extent than butter. The effect of coconut consumption on the ratio of total cholesterol to high-density lipoprotein cholesterol was often not examined.
[1919] Khaw KT et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ Open 2018;8(3):e020167. . 2018. Link
INTRODUCTION: High dietary saturated fat intake is associated with higher blood concentrations of low-density lipoprotein cholesterol (LDL-C), an established risk factor for coronary heart disease. However, there is increasing interest in whether various dietary oils or fats with different fatty acid profiles such as extra virgin coconut oil may have different metabolic effects but trials have reported inconsistent results. We aimed to compare changes in blood lipid profile, weight, fat distribution and metabolic markers after four weeks consumption of 50 g daily of one of three different dietary fats, extra virgin coconut oil, butter or extra virgin olive oil, in healthy men and women in the general population. DESIGN: Randomised clinical trial conducted over June and July 2017. SETTING: General community in Cambridgeshire, UK. PARTICIPANTS: Volunteer adults were recruited by the British Broadcasting Corporation through their websites.
[1920] Neelakantan N et al. The effect of coconut oil consumption on cardiovascular risk factors: a systematic review and meta-analysis of clinical trials. Circulation 2020;141(10):803–814. . 2020. Link
A systematic review and meta-analysis of clinical trials on the effect of coconut oil consumption on cardiovascular risk factors.
[1921] Marina AM et al. Antioxidant capacity and phenolic acids of virgin coconut oil. Int J Food Sci Nutr 2009;60(Suppl 2):114–123. . 2009. Link
The antioxidant properties of virgin coconut oil produced through chilling and fermentation were investigated and compared with refined, bleached and deodorized coconut oil. Virgin coconut oil showed better antioxidant capacity than refined, bleached and deodorized coconut oil. The virgin coconut oil produced through the fermentation method had the strongest scavenging effect on 1,1-diphenyl-2-picrylhydrazyl and the highest antioxidant activity based on the beta-carotene-linoleate bleaching method. However, virgin coconut oil obtained through the chilling method had the highest reducing power. The major phenolic acids detected were ferulic acid and p-coumaric acid. Very high correlations were found between the total phenolic content and scavenging activity (r=0.91), and between the total phenolic content and reducing power (r=0.96).
[1922] Lieberman S et al. A review of monolaurin and lauric acid: natural virucidal and bactericidal agents. Altern Complement Ther 2006;12(6):310–314. . 2006. Link
Review of monolaurin and lauric acid as potential natural virucidal and bactericidal agents, framed by the problem of antibiotic resistance. The authors report that monolaurin has substantially greater virucidal and bactericidal activity than lauric acid itself, with in vitro efficacy against lipid-coated viruses and Gram-positive bacteria (e.g., Staphylococcus aureus, Streptococcus pyogenes). Of note, the article is a narrative rather than systematic review.
[1923] Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr 1982;36(5):950–962. (klasszikus MCT-definíció). . 1982. Link
A review of the literature on the medical and nutritional use of medium-chain triglycerides (MCTs) since 1970 is presented with additional discussions on the various modifications and applications of the MCTs in the synthesis of certain structured lipids. The metabolism of MCTs in the liver and extrahepatic tissues is discussed along with further documentation of the use of MCTs in malabsorption and hyperlipidemia cases. Recent applications of MCTs and modified MCTs in hyperalimentation, deficiency in the carnitine system, epilepsy, obesity, and other special areas of application are cited. The use of medium-chain monodiglycerides for dissolving cholesterol gallstones is presented. The contraindications for the use of MCTs in ketosis, acidosis, and cirrhosis are also discussed. Suggestions for use of MCTs in a variety of medical and nutritional applications are presented.